Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition

Journal of Assisted Reproduction and Genetics

Volumn 32, Issue 7, 2015, Pages 1063-1068

  Santos Ribeiro, Samuel ^a,b   Polyzos, Nikolaos P ^a,c   Stouffs, Katrien ^d   De Vos, Michel ^a   Seneca, Sara ^d   Tournaye, Herman ^a   Blockeel, Christophe ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Freeze all strategy; GnRH agonist triggering; GnRH antagonist; OHSS free clinic; Ovarian hyperstimulation syndrome

Indexed keywords

ALBUMIN; CABERGOLINE; GONADORELIN AGONIST; RECOMBINANT FOLLITROPIN; GONADORELIN;

ADULT; ARTICLE; ASCITES; CASE REPORT; CRYOPRESERVATION; DISEASE SEVERITY; EXOME; FEMALE; GENE SEQUENCE; GENETIC PREDISPOSITION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; NUCLEOTIDE SEQUENCE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; AGONISTS; GENETICS; HUMAN GENOME; MALE; OOCYTE RETRIEVAL; PREGNANCY;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OOCYTE RETRIEVAL; OVARIAN HYPERSTIMULATION SYNDROME; POLYCYSTIC OVARY SYNDROME; PREGNANCY; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 84938963045     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-015-0498-y     Document Type: Article

References (39)

1. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85(1):112–20. doi:10.1016/j.fertnstert.2005.07.1292.
2. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73(5):901–7.
3. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84–91. doi:10.1016/j.fertnstert.2007.02.002.
4. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86(6):1682–7. doi:10.1016/j.fertnstert.2006.05.049.
5. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9(1):77–96.
6. Vloeberghs V, Peeraer K, Pexsters A, D’Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23(5):691–709. doi:10.1016/j.bpobgyn.2009.02.006.
7. Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17(4):510–24. doi:10.1093/humupd/dmr008.
8. Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril. 2012;97(3):531–3. doi:10.1016/j.fertnstert.2011.12.020.
9. Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril. 2012;97(3):527–8. doi:10.1016/j.fertnstert.2011.12.010.
10. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12(2):159–68. doi:10.1093/humupd/dmi045.
11. Herrero L, Pareja S, Losada C, Cobo AC, Pellicer A, Garcia-Velasco JA. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome. Fertil Steril. 2011;95(3):1137–40. doi:10.1016/j.fertnstert.2010.09.040.
12. Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod. 2013;28(9):2529–36. doi:10.1093/humrep/det304.
13. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009;19(4):486–92. doi:10.1016/j.rbmo.2009.06.001.
14. Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod. 2011;26(10):2593–7. doi:10.1093/humrep/der251.
15. Bodri D, Guillén JJ, Trullenque M, Schwenn K, Esteve C, Coll O. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril. 2010;93(7):2418–20. doi:10.1016/j.fertnstert.2009.08.036.
16. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril. 2011;95(6):2029–33. doi:10.1016/j.fertnstert.2011.01.163.
17. Ling LP, Phoon JW, Lau MS, Chan JK, Viardot-Foucault V, Tan TY, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at ‘freeze-all strategy’. Reprod Biomed Online. 2014;29(3):392–4. doi:10.1016/j.rbmo.2014.05.012.
18. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online. 2014. doi:10.1016/j.rbmo.2014.07.022.
19. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008–11. doi:10.1016/j.fertnstert.2014.01.019.
20. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44(6):430–40.
21. Kol S. A case of severe early-onset OHSS after GnRH-agonist triggering. Fertil Steril. 2011;96(3):e151. doi:10.1016/j.fertnstert.2011.06.057. author reply e152.
22. Abu-Louz SK, Ahmed AA, Swan RW. Spontaneous ovarian hyperstimulation syndrome with pregnancy. Am J Obstet Gynecol. 1997;177(2):476–7.
23. Ayhan A, Tuncer ZS, Aksu AT. Ovarian hyperstimulation syndrome associated with spontaneous pregnancy. Hum Reprod. 1996;11(8):1600–1.
24. Di Carlo C, Bruno P, Cirillo D, Morgera R, Pellicano M, Nappi C. Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. Hum Reprod. 1997;12(10):2115–7.
25. group E-A-sPcw. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.
26. Altmae S, Hovatta O, Stavreus-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17(6):813–28. doi:10.1093/humupd/dmr034.
27. Moron FJ, de Castro F, Royo JL, Montoro L, Mira E, Saez ME, et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics. 2006;16(7):485–95. doi:10.1097/01.fpc.0000215073.44589.96.
28. Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009;19(1):14–27.
29. O’Brien TJ, Kalmin MM, Harralson AF, Clark AM, Gindoff I, Simmens SJ, et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol RB&E. 2013;11(1):71. doi:10.1186/1477-7827-11-71.
30. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril. 2009;91(2):432–9. doi:10.1016/j.fertnstert.2007.11.093.
31. Daelemans C, Smits G, de Maertelaer V, Costagliola S, Englert Y, Vassart G, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab. 2004;89(12):6310–5. doi:10.1210/jc.2004-1044.
32. Dulitzky M, Cohen SB, Inbal A, Seidman DS, Soriano D, Lidor A, et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 2002;77(3):463–7.
33. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–11.
34. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–4. doi:10.1093/nar/gkg509.
35. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9. doi:10.1038/nmeth0410-248.
36. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750. doi:10.1002/14651858.CD001750.pub3.
37. Humaidan P. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertil Steril. 2012;97(3):529–30. doi:10.1016/j.fertnstert.2011.11.016.
38. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod. 2007;22(5):1348–52. doi:10.1093/humrep/dem006.
39. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013;28(9):2522–8. doi:10.1093/humrep/det124.